Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-7913, ONO-4538, and FOLFOX with Bevacizumab or Cetuximab in Advanced Colorectal Cancer
NCT06540261Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Sep 2021
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of magrolimab in colorectal cancer (CRC) (2 arms), sponsored by Ono Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Adverse event. Started Sep 2021; status: active, not recruiting.
02
Drugs
magrolimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06540261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06540261.